4/24
10:27 am
dmac
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $8.00 price target on the stock.
Low
Report
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $8.00 price target on the stock.
4/18
12:09 pm
dmac
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch [Yahoo! Finance]
Low
Report
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch [Yahoo! Finance]
4/17
04:19 pm
dmac
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke [Yahoo! Finance]
Medium
Report
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke [Yahoo! Finance]
4/17
04:08 pm
dmac
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Medium
Report
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
4/15
10:48 am
dmac
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Neutral
Report
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
3/25
10:11 am
dmac
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/21
02:32 pm
dmac
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its price target lowered by analysts at Craig Hallum from $11.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its price target lowered by analysts at Craig Hallum from $11.00 to $8.00. They now have a "buy" rating on the stock.
3/21
09:37 am
dmac
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $6.00 price target on the stock, down previously from $7.00.
Medium
Report
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $6.00 price target on the stock, down previously from $7.00.
3/21
06:44 am
dmac
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Path To Profitability [Yahoo! Finance]
Medium
Report
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Path To Profitability [Yahoo! Finance]
3/19
04:30 pm
dmac
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results [Yahoo! Finance]
3/19
04:15 pm
dmac
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Low
Report
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
1/29
04:24 pm
dmac
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference [Yahoo! Finance]
Medium
Report
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference [Yahoo! Finance]
1/29
04:13 pm
dmac
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
Medium
Report
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference